BNRG stock touches 52-week low at $0.5 amid market challenges

Published 22/05/2025, 15:50
BNRG stock touches 52-week low at $0.5 amid market challenges

Brenmiller Energy Ltd (BNRG) stock has hit a 52-week low, dropping to $0.5, as the company faces a tumultuous period in the energy sector. According to InvestingPro data, the stock’s RSI indicates oversold territory, while the company’s overall financial health score stands at a concerning 1.19, labeled as ’WEAK’. This new low comes as a stark contrast to its performance over the past year, with Brenmiller Energy experiencing a significant downturn of -64.52% in its year-over-year change. The company’s rapid cash burn rate and negative EBITDA of -$10.11M highlight ongoing challenges. InvestingPro subscribers can access 12 additional key insights about BNRG’s financial position. Investors are closely monitoring the company’s strategy and market conditions, as the stock’s current position reflects broader trends and investor sentiment within the renewable energy industry.

In other recent news, Brenmiller Energy Ltd. has announced a public offering aiming to raise approximately $1.5 million through the issuance of ordinary shares and warrants. The offering is set to close in May 2025, subject to customary conditions, with A.G.P./Alliance Global Partners (NYSE:GLP) acting as the sole placement agent. The company plans to use the proceeds for general corporate purposes, including working capital and capital expenditures. Additionally, Brenmiller Energy outlined a strategic shift in its corporate structure, focusing on the creation of European subsidiaries to attract private capital. This move is part of their strategy to accelerate the path to positive cash flow and optimize financial profiles. Meanwhile, DarioHealth (NASDAQ:DRIO) Corp. has appointed Chen Franco-Yehuda as the new Chief Financial Officer, following the planned retirement of Zvi Ben-David. Franco-Yehuda, who previously held similar roles at Pluri Inc., is expected to bring significant expertise in financial strategy and capital markets to DarioHealth. CEO Erez Raphael expressed confidence in Franco-Yehuda’s ability to contribute to the company’s continued growth.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.